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Background
Monotherapy with Ipilimumab (anti-CTLA-4 antibody)
and monotherapy with IL-2 (T cell stimulating cytokine)
are approved for the treatment of metastatic melanoma.
Combination immunotherapy has been suggested as a
more potent regimen but has not been sufficiently
investigated. We hypothesized that this combination
may enhance therapeutic responses through alteration
of the effector CD8+ T cell to CD4+FoxP3+ regulatory
T cell ratio.
Methods
On day 0, C57BL/6 mice were challenged via intrader-
mal injection with B16-F10 melanoma (120,000 cells).
To track anti-tumor CD8+ T cell responses, pmel CD8+
T cells (specific against melanoma antigen gp100; 50,000
cells) were adoptively transferred via retroorbital injec-
tion. On days 3, 6, and 9 anti-CTLA-4 (100 µg in 100 µl
or 100 µg IgG control) was administered via intraperito-
neal injection. On days 4-8 IL-2 (100,000 units in 100 µl
or 100µl PBS) was administered every 12 h. Tumor area
was measured every 2-3 days until reaching 100 mm2 or
until mice were sacrificed for flow cytometry analysis of
T cell responses in the tumor and tumor-draining
lymph nodes.
Results
Tumor growth was significantly reduced with combina-
tion anti-CTLA-4 and IL-2 treatment (average tumor
area: 2mm2 on day 14) compared to anti-CTLA-4 only,
IL-2 only, and placebo treatment (14, 29, and 68 mm2,
respectively, on day 14) (p < 0.01 for all comparisons).
On day 4, regulatory T cells were decreased by 20% in
the tumor with anti-CTLA-4 therapy alone or in combi-
nation with IL-2, compared to placebo. By day 10, regu-
latory T cells decreased by 80% in the tumor, but
increased three-fold in the tumor-draining lymph nodes,
compared to placebo (p < 0.01 for all comparisons). In
the tumor microenvironment, anti-tumor (pmel) CD8+
T cells were increased 2-fold with IL-2 therapy alone or
in combination with anti-CTLA-4, compared to placebo
(p < 0.01). This resulted in a pmel CD8+ T cell/Treg
ratio of >10 with combination immunotherapy com-
pared to ratios of 3, 1.3, and 0.7 for anti-CTLA-4 only,
IL-2 only, and placebo treatments, respectively.
Conclusions
Combination immunotherapy with anti-CTLA-4 and IL-
2 increases the tumor-specific CD8+ T cell/regulatory
CD4+ T cell ratio in the tumor microenvironment and
significantly decreases tumor growth (compared to
monotherapy alone or placebo). These findings propose
a previously unrecognized mechanism for anti-CTLA-4
in which regulatory CD4+ T cells are redirected out of
the tumor microenvironment into the tumor-draining1Rush University Medical Center, Chicago, IL, USA
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lymph nodes. These data highlight the potential syner-
gistic action of anti-CTLA-4 combined with IL-2 for the
treatment of melanoma.
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